Výsledky vyhledávání

A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer

Autor: Colin Mansfield, Patrick J. Flynn, Lemuel A. Moyé, Gael Deplanque, James M Atkins, Patrice Dubreuil, Yolene Acin, Alain Moussy, E. Nowara, Mohamed Hebbar, Olivier Hermine, David Piquemal, Pascal Hammel, Martin Demarchi, Bohuslav Melichar, D. Ritter

Publikováno v: Annals of Oncology

Two subgroups showing significantly poor survival when treated with single-agent gemcitabine have been identified; one is defined by an overexpression of ACOX1 in blood, and the other via a pain intensity threshold. Masitinib in combination with gemc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f3aeda9b81af683bb70bcccaa21d2ab
https://doi.org/10.1093/annonc/mdv133

Zobrazit plný text záznamu

Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: A randomized controlled open-label trial

Autor: Antoine Adenis, B. Bui-Nguyen, J.-Y. Blay, V. R. Bulusu, A. Blesius, François Bertucci, I.L. Ray-Coquard, Olivier Bouché, Patrice Dubreuil, Alain Moussy, Emmanuelle Bompas, Colin Mansfield, Yolene Acin, Olivier Hermine, N. Isambert, A. Le Cesne, Julien Domont, B.A. Van Tine, Loic Chaigneau

Publikováno v: Annals of Oncology

These findings may potentially influence future clinical practice, with encouraging long-term survival data and better safety of masitinib with respect to sunitinib indicating a positive benefit–risk ratio. Considered in the setting of effective su

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08e670b2164feab9b86294c8f18d43bf
https://doi.org/10.1093/annonc/mdu237

Zobrazit plný text záznamu

In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells

Autor: Katia Hanssens, Erinn Soucie, Olivier Hermine, Paulo De Sepulveda, Thomas Mercher, Cristina Bulai Livideanu, Patrice Dubreuil, Sophie Georgin-Lavialle, Gandhi Damaj, M.-O. Chandesris, Olivier A. Bernard, Yolene Acin, Sébastien Letard

Publikováno v: Blood. 120:4846-4849

Although a role for oncogenic KIT in driving mast cell disease is clear, the mechanisms driving the multiple phenotypic and clinical manifestations of this disorder are not well elucidated. We now show, using a large cohort of mastocytosis patients,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1ea04a9738c705a228313e422cf970b
https://doi.org/10.1182/blood-2011-12-397588

Zobrazit plný text záznamu

Masitinib in comparison to imatinib as first-line therapy of patients with advanced gastrointestinal stromal tumor (GIST): A randomized phase III trial

Autor: Loic Chaigneau, Laurent Mineur, Olivier Hermine, Binh Bui Nguyen, Nicolas Isambert, Olivier Bouché, Nicolas Penel, Pierre Michel, Antoine Adenis, Alain Moussy, Yolene Acin, Tanios Bekaii-Saab, François Bertucci

Publikováno v: Journal of Clinical Oncology. 30:TPS10102-TPS10102

TPS10102^ Background: Masitinib is an oral tyrosine kinase inhibitor (TKI) that has greater in vitro kinase activity and/or selectivity than imatinib against KIT and PDGFRA/B. A phase 2 study has previously reported that masitinib treatment produced

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4f31bea8b776b3057a2d8e19179e4aa5
https://doi.org/10.1200/jco.2012.30.15_suppl.tps10102

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání